Endometriosis Drugs Market Will Achieve Sales of $1.92 Bn Worldwide in 2020

Thursday 31 March 2016, Amsterdam

A new report, now available on ASDReports, forecasts that the endometriosis drugs market will achieve sales of $1.92 billion worldwide in 2020. That pharma market will experience revenue growth from 2016 to 2026, adapting to driving and restraining forces – changes, opportunities and threats. That revenue prediction and others appear in Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder.

The key player published that report in February 2016. That company is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand potentials of industries and markets in healthcare and other fields.

10% of women worldwide have endometriosis, giving high, rising demand for medicines. In 2014 Lupron was the leading product for revenue generation in the endometriosis drugs market, accounting for 8.9% of that world market. Visanne became the second-highest selling drug in the endometriosis medicines market. The top five endometriosis drugs accounted for 30.2% of the total market. In 2014 and 2015, the US formed the leading national market for endometriosis therapies. Japan held second place for revenue generation from endometriosis-treating drugs. This study predicts that India will form the fastest growing emerging market there from 2016 to 2026. In 2014 AbbVie was the leading company, in a market holding some of the world’s largest pharmaceutical developers, producers and marketers.

From 2016 endometriosis treatment will face challenges through healthcare reforms and budgetary restrictions, but will benefit from increasing awareness of that women’s disease. That industry will also benefit from the launch of new products, from strong R&D in 2016. Success of that market will depend on awareness programmes and increasing demand from women for treatment, with rising disease incidence and improving diagnosis methods. Those developments give opportunity for healthcare companies to gain success by launching novel medicines and medical devices to suit patients’ needs worldwide.

Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “Endometriosis is one of the most widespread chronic conditions in women. Current diagnostic and treatment strategies possess limitations, reportedly causing side effects and inconvenience to patients. Many pharmaceutical companies are developing novel medicines with different therapeutic targets for treating endometriosis. The need for advances in medical technologies for better diagnoses and treatment for endometriosis expands, giving opportunities for companies and healthcare providers. And better treatment of endometriosis depends on greater understanding of the disease in medical science and the pharma industry, as well as more awareness programmes by healthcare providers.”

That therapeutic segment holds promising R&D. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, the study notes. There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients.